Latest Thiophenes Stories
Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor, was used instead of the standard treatment, clopidogrel. Professor Storey's latest findings were presented at the British Cardiovascular Society annual scientific conference in Manchester today (Monday 13 June 2011).Professor Storey has led UK...
BRUSSELS, June 10, 2011 /PRNewswire/ -- Results from new post hoc analyses assessing the effects of Neupro® (rotigotine transdermal system) in Restless Legs Syndrome (RLS) and utilizing novel surrogate markers suggested improved daytime functioning and daytime symptoms, reduced RLS-related pain and improved mood and depressive symptoms in patients with moderate to severe RLS. The data were presented at the 15th International Congress of Parkinson's disease and Movement disorders in...
BRUSSELS, June 9, 2011 /PRNewswire/ -- A post hoc analysis from the RECOVER study (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine Transdermal System) suggested that patients with Parkinson's disease who used Neupro® (rotigotine transdermal system) may experience improvements in key markers of mood/cognition, such as taking interest in surroundings and getting pleasure out of life. Additional data presented from a one year open label follow-up of RECOVER supported...
CUPERTINO, Calif., June 3, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and CEO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 7 at 4:30 p.m. Eastern time. The conference is being held at the Grand Hyatt in New York. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor...
CUPERTINO, Calif., June 2, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer, Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities. Dr. Stauffer and DURECT have entered into a consulting agreement through December 31, 2011. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) "We appreciate all of Joe's efforts over the last two years, most notably in...
SAN DIEGO, May 17, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity (also termed poor responders) on antiplatelet therapy (e.g. clopidogrel) who are at greater risk for future cardiovascular events....
CUPERTINO, Calif., May 12, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24 at 10:00 a.m. London Time. The conference is being held at the UBS offices in London, England (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...
SAN DIEGO, May 11, 2011 /PRNewswire/ -- Accumetrics, Inc., marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed a national distribution agreement with Cardinal Health, Inc. to distribute the VerifyNow System to hospitals, health systems and independent laboratories throughout the United States. The VerifyNow System is widely used by...
WAYNE, Pa., May 10, 2011 /PRNewswire/ -- Pierrel Research USA, Inc. (www.pierrel-research-usa.com), a subsidiary of Pierrel SpA, the Italian-based, global pharmaceutical services company (www.pierrel.it), announces the US launch of Orabloc(TM) (Articaine hydrochloride 4% with epinephrine 1:100,000 and Articaine hydrochloride 4% with epinephrine 1:200,000). Orabloc is a new purer formulation of Articaine with epinephrine, an injectable dental anesthetic for routine dental procedures and oral...
REDWOOD CITY, Calif., May 6, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at The Tenth Annual JMP Securities Research Conference at the San Francisco Ritz Carlton. The presentation is scheduled for Monday, May 9, 2011 at...
